Pancreatic Adenocarcinoma Treatment Market Size & Share, by Type (Chemotherapy, Targeted Therapy); Affected Area (Exocrine, Endocrine) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 3373
Published Date: Apr 01, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Pancreatic Adenocarcinoma Treatment Landscape

Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
F. Hoffman-La Roche AG
Novartis AG
Pfizer Inc.
Aduro Biotech Inc.
Clovis Oncology Inc.
Threshold Pharmaceuticals Inc.
NewLink Genetics Corp
Infinity Pharmaceuticals Inc.
Celgene Corporation

Browse Key Market Insights with Data Illustration:

Pancreatic Adenocarcinoma Treatment Market Size & Share, Growth Trends 2035

In the News

Amgen Inc.’s new drug targeting KRAS mutations was approved by the U.S. Food and Drug Administration. This is the first-ever therapy developed to treat KRAS cancers, which are often altered in the colon, lung, and pancreatic areas.
Novartis AG declared that US Food and Drug Administration granted the NIS793 with Orphan Drug Designation (ODD) along with standard chemotherapy care for the treatment of pancreatic cancer.

Frequently Asked Questions (FAQ)

The major factors driving the market growth are the increasing geriatric population around the world and the rising prevalence of obesity.

The market size of pancreatic adenocarcinoma treatment is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023-2035.

Lack of skilled professionals and side effects of chemo and radiotherapy are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., Threshold Pharmaceuticals Inc., NewLink Genetics Corp, Infinity Pharmaceuticals Inc., Celgene Corporation.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, affected area, and by region.

The exocrine segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Pancreatic Adenocarcinoma Treatment Market Size & Share, by Type (Chemotherapy, Targeted Therapy); Affected Area (Exocrine, Endocrine) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Companies Dominating the Pancreatic Adenocarcinoma Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the pancreatic adenocarcinoma treatment market?

What would be the CAGR of pancreatic adenocarcinoma treatment market over the forecast period?

What are the challenges affecting the pancreatic adenocarcinoma treatment market growth?

Which region will provide more business opportunities for growth of pancreatic adenocarcinoma treatment market in future?

Who are the major players dominating the pancreatic adenocarcinoma treatment market?

How are the company profiles selected?

What are the segments in the pancreatic adenocarcinoma treatment market?

Which segment captures the largest market size in the type segment in the pancreatic adenocarcinoma treatment market?